Not checkedNot checked for notices yet.
Quantitative evaluation of interim positron emission tomography in peripheral T-cell lymphoma
Lars Kurch, Ulrich Dührsen, Andreas Hüttmann and 4 more
EJNMMI Research · 2021
doi:10.1186/s13550-021-00827-1 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Background Interim [ 18 F]fluoro-deoxyglucose-positron emission tomography predicts outcome in peripheral T-cell lymphoma (PTCL). We compared two quantitative evaluation methods. Methods Interim scans from 43 patients with anaplastic lymphoma kinase-negative PTCL from the ‘Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas’ trial were re-analyzed by qPET (relating residual lymphoma-related uptake to liver uptake) and ∆SUV max (relating interim scan to baseline scan). The endpoint was progression-free survival. Results qPET and ∆SUV max were closely correlated (Pearson’s r = 0.627). Up to the 60 th percentile of values ranked by increasing residual activity, the positive predictive value for progression or death increased from 60 to 95%, with stable negative predictive values (NPV) of 60%. Beyond the 60 th percentile, the NPV decreased to 40%. qPET ≥ 2 and ∆SUV max < 50% identified high-risk populations comprising 41.9% and 39.5% of patients, with 3-year progression-free survival rates of 5.6% (95% confidence interval, 0.8–37.3) and 0%, respectively, as compared to 63.7% (47.4–85.8) and 61.3% (45.1–83.3) in low-risk patients. Conclusions qPET and ∆SUV max identify large fractions of PTCL patients destined to experience treatment failure. qPET may be preferred because it requires a single PET scan, halving the diagnostic effort.
Abstract licence: CC BY-NC-ND
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.